Clinical Trials Browser

Phase 1 × Terminated × avelumab × Clear all

Lymphoma, Lymphoma, Follicular

NCT02994953 2024-09-20

COMBO

Phase 1 Terminated

52 enrolled 34 charts

Other solid neoplasm

Advanced Solid Tumors

NCT03451825 2024-06-24

Phase I/II Study of Avelumab in Pediatric Cancer Participants

Phase 1 Terminated

21 enrolled 21 charts

CNSLymphoid

Lymphoma, Central Nervous System Neoplasms

NCT03915405 2024-04-25

KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer

Phase 1 Terminated

16 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT03861403 2023-11-30

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Phase 1 Terminated

10 enrolled

BreastGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Recurrence

NCT04551885 2023-09-21

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Phase 1 Terminated

12 enrolled

BreastDermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Phase 1 Terminated

5 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03267836 2023-06-15

Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma

Phase 1 Terminated

9 enrolled

CNS

Meningioma

NCT03502681 2022-07-01

A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients

Phase 1 Terminated

6 enrolled 12 charts

Genitourinary

Metastatic Urothelial Cell Cancer

NCT02603419 2020-04-24

JAVELIN HODGKINS

Phase 1 Terminated

34 enrolled 43 charts

Lymphoid

Hodgkin Disease, Recurrence

NCT03395873 2019-08-21

Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy

Phase 1 Terminated

7 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Clinical Trials

Rituximab + Immunotherapy in Follicular Lymphoma

COMBO

Phase I/II Study of Avelumab in Pediatric Cancer Participants

KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma

A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients

JAVELIN HODGKINS

Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy